=== PAGE 3 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is all the text content extracted from the PDF page, preserving its original layout and structure:

1. Crenolanib, whether delivered by itself or as part of a drug combination, has shown benefit in FLT3 mutant AML.
2. Patients who progress after treatment with prior TKIs may still remain sensitive to crenolanib.
3. Crenolanib has favorable pharmacokinetics and does not accumulate with repeated dosing.
4. Crenolanib is a selective type I TKI that does not inhibit wild-type cKIT.

---
An image is present on the left side of the page, depicting hands holding what appears to be a newspaper or document. Overlaid on this image in large white text is "crenolanib in the news", indicating the theme of the adjacent content.

On the right side of this section, a list of news items/presentations is provided:
Arog Pharmaceuticals Presents Crenolanib Clinical Data at
the 2018 European Hematology Association Meeting

Arog Pharmaceuticals Presents Crenolanib Clinical Data at
the 2017 American Society of Clinical Oncology Annual
Meeting

Arog Pharmaceuticals Presents Crenolanib Clinical Data at
57th American Society of Hematology Annual Meeting

Arog Pharmaceuticals Receives Orphan Drug Designation
in the European Union for Crenolanib for the Treatment of
Acute Myeloid Leukemia and Soft Tissue Sarcoma

AROG Pharmaceuticals to Present Clinical Data on
Crenolanib at the 2016 American Society of Hematology
Annual Meeting

Arog Pharmaceuticals Receives FDA Fast Track
Designation for Crenolanib for Advanced Gastrointestinal
Stromal Tumors with a D842V Mutation in the PDGFRA
Gene

Arog Pharmaceuticals Presents Crenolanib Clinical Data at
the 2016 American Society of Clinical Oncology Annual
Meeting
---

An image spans the width of the lower part of the page, showing a blurred audience in a dimly lit conference or presentation hall. Superimposed on this image in large white text are the words "recent conference presentations," serving as a section header for related content.

---

1. Collins R, Kantarjian HM, Levis MJ, et al. Clinical Activity Of Crenolanib In Patients With D835 Mutant FLT3-Positive
Relapsed/Refractory Acute Myeloid Leukemia (AML). J Clin Oncol 2014; 32:5s (suppl; abstr 7027).
